Back to News
Market Impact: 0.2
NeuroSense Appeals Nasdaq Delisting Determination, Hearing Date Set For Nov. 10
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
NeuroSense Therapeutics said its Nasdaq Hearings Panel hearing is scheduled for November 10, 2026, after the company appealed an October 1, 2026 decision. The available article text does not specify the decision or the potential outcome of the hearing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
NRSN-0.20
More News
- Kraken parent company Payward to become first crypto firm to buy a European Bank
- How CFOs at Chevron, ServiceNow and Nasdaq decide which AI bets create value
- Rare Earths Stock Extends Slide, Eyes 52-Week Low
- Lithium Stock Looks to End Losing Streak After Upgrade
- UBS considers leaving Switzerland over capital rule plans, WSJ reports
- Bank of America Has 'Accountability' in Face of Fines, Says Moynihan